<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1703257078
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XEVANEER 125mg/5ml Powder For Oral Suspension
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFDINIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Xevaneer</strong><sup>&reg;</sup> contains cefdinir as the active ingredient. Cefdinir is a broad spectrum semisynthetic cephalosporin antibiotic for oral administration.</p><p>The bactericidal mode of action of <strong>Xevaneer</strong><sup>&reg;</sup> is a result of the inhibition of cell wall synthesis. <strong>Xevaneer</strong><sup>&reg;</sup> is highly beta-lactamase stable and as a result, many organisms resistant to penicillins and some cephalosporins, due to the presence of beta-lactamases, are susceptible to <strong>Xevaneer</strong><sup>&reg;</sup>.</p><p>Most strains of the following Gram-positive and Gram negative organisms have been shown to be susceptible to cefdinir: <em>Staphylococcus species</em>, <em>Streptococcus pneumoniae</em>, <em>Streptococcus pyogenes</em>, <em>Streptococcus agalactiae</em>, and <em>Streptococcus viridans</em>; <em>Haemophilus influenzae</em>, <em>Haemophilus parainfluenzae</em>, <em>Moraxella catarrhalis</em>, <em>Neisseria gonorrhea</em> and <em>meningitidis</em>, <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, <em>Proteus mirabilis</em>, and <em>Citrobacter diversus.</em></p><p>Therefore <strong>Xevaneer</strong><sup>&reg;</sup> is indicated in the treatment of:</p><ul><li>Upper respiratory tract infections e.g. pharyngitis, tonsillitis, acute maxillary sinusitis.</li><li>Lower respiratory tract infections e.g. pneumonia, bacterial bronchitis, acute exacerbations of chronic bronchitis,</li><li>Middle ear infection e.g. acute otitis media</li><li>Uncomplicated skin and skin structure infections</li><li>Urinary tract infections.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Xevaneer</strong><strong><sup>&Ograve;</sup></strong></p><p>&sect;&nbsp; If you are allergic (hypersensitive) to cefdinir, cephalosporin, penicillin group of antibiotics or any other ingredients of Xevaneer&reg;</p><p><strong>&nbsp;</strong></p><p><strong>Take special care with Xevaneer</strong><strong><sup>&Ograve;</sup></strong></p><p>&sect;&nbsp; If you have had hypersensitivity to cefdinir, other cephalosporins or penicillins</p><p>&sect;&nbsp; If you have a history of colitis</p><p>&sect;&nbsp; If you are pregnant you should not take cefdinir during pregnancy unless it is clearly needed (rated FDA pregnancy category B). There are no adequate and well-controlled studies have been performed in pregnant women. Cefdinir is not detected in human breast milk after administration of 600 mg doses.</p><p>&sect;&nbsp; If you have renal insufficiency the total daily dose of cefdinir should be reduced.</p><p>&nbsp;</p><p><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Antacids and iron supplements</strong>: You should take <strong>Xevaneer</strong><sup>&reg;</sup> at least 2 hours before or after the antacid or iron supplement.</p><p>If you are receiving cefdinir with iron containing products, you may experience reddish stool due to the formation of a non-absorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.</p><p><strong>Probenecid</strong>: Probenecid inhibits the renal excretion of cefdinir resulting in higher serum concentrations and a longer half-life.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breastfeeding</strong></p><p>If you are pregnant you should not take cefdinir during pregnancy unless it is clearly needed (rated FDA pregnancy category B). There are no adequate and well-controlled studies have been performed in pregnant women. Cefdinir is not detected in human breast milk after administration of 600 mg doses.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of </strong><strong>Xevaneer</strong><strong><sup>&Ograve;</sup></strong></p><p><strong>Xevaneer<sup>&reg;</sup> suspension contains approximately 2.9 grams sucrose per 5 ml;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This should be taken into account in patients with diabetes mellitus.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sucrose may be harmful to the teeth.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <strong>Xevaneer</strong><sup>&reg;</sup> exactly as your doctor or health care provider has told you. You should check with your doctor or pharmacist if you are not sure.</p><p><strong><em>Children:</em></strong></p><p>The recommended dose is 7 mg/kg of suspension every 12 hours or 14 mg/kg once daily up to a maximum of 600 mg per day. <strong>Xevaneer</strong><sup>&reg;</sup> suspension should be administered twice daily in skin infections in children.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Dose of (125mg/5ml suspension)</strong>*</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2.5 ml (0.5 tsp) q 12 hr or 5 ml (1 tsp) q 24 h</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>5 ml (1 tsp) q 12 hr or 10 ml (2 tsp) q 24 h</p></td></tr><tr><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>7.5 ml (1.5 tsp) q 12 hr or 15 ml (3 tsp) q 24 h</p></td></tr></tbody></table><p>* After reconstitution</p><p>Children weighting more than 43 kg should receive the maximum daily dose of 600 mg.</p><p><u>For reconstitution: </u></p><ul><li>Invert the bottle and shake content to loosen powder, add pre-boiled cooled water to the mark, and shake well, then add more water if necessary up to the mark and shake well until a homogeneous suspension is obtained.</li><li>When first reconstituted, allow to stand for five minutes to ensure full dispersion.</li><li>Shake well before use.</li></ul><p><u>Renal impairment</u></p><p>Cefdinir is renally excreted.</p><p><em>Adults:</em></p><p>When creatinine clearance &lt; 30 ml/min, the recommended dose of <strong>Xevaneer</strong><sup>&reg;</sup> is 300 mg given once daily.</p><p><em>Children</em>:</p><p>Pediatric patients with a creatinine clearance of &lt;30 ml/min/1.73 m<sup>2</sup> should receive <strong>Xevaneer</strong><sup>&reg;</sup> 7 mg/kg (up to 300 mg) given once daily.</p><p>If you are on haemodialysis the recommended dosage is 300 mg or 7 mg/kg every other day.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Xevaneer</strong><strong><sup>&Ograve;</sup></strong><strong><sup> </sup></strong><strong>than you should</strong></p><p>Cefdinir is removed from the body by haemodialysis. No information regarding cefdinir overdosage is available but overdosage with other &beta;-lactam antibiotics has resulted in nausea, vomiting, epigastric distress, diarrhea and convulsions.</p><p>&nbsp;</p><p><strong>If you forget to take Xevaneer</strong><strong><sup>&Ograve;</sup></strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Xevaneer</strong><sup>&reg;</sup> can cause side effects, although not everybody gets them.</p><p>Side effects are mild and transient in nature; most of them being diarrhea, abdominal pain, nausea, vomiting, skin rash, transient elevation in liver enzymes.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Xevaneer</strong><strong><sup>&Ograve;</sup></strong> after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Discard unused content 10 days after reconstitution.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xevaneer<sup>&reg; </sup>125mg/5ml Suspension: After reconstitution, each 5 ml contains 125 mg Cefdinir.</p><p>Inactive ingredients: Tribasic sodium citrate, colloidal anhydrous silica, magnesium stearate, sodium benzoate, citric acid, sucrose, xanthan gum, guar gum, strawberry flavor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Xevaneer® suspension is available in bottles containing powder sufficient to prepare 40 ml or 80 ml suspension. These bottles contain white to off white powder.
Not all pack sizes may be marketed 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment Co. Ltd. (Na&#39;ur - Jordan)</p><p>Tel. (+962 6) 57 27 132</p><p>Fax. (+962 6) 57 27 776</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي <strong>زيفانير</strong> على المادة الفعالة سفدنير. سفدنير هو مضاد حيوي ينتمي إلى مجموعة السيفالوسبورينات نصف مخلق واسع الطيف، يعطى عن طريق الفم.</p><p>يمتلك<strong> سفدنير </strong>فاعليته القاتلة للبكتيريا عن طريق تثبيطه لعملية تخليق جدار الخلية<strong>. زيفانير</strong> ذو ثباتية عالية تجاه البيتا-لاكتاميز، ولذا فإن العديد من البكتيريا المقاومة للبنسلينات ولبعض السيفالوسبورينات كنتيجة لإفراز البيتا-لاكتاميز، تكون حساسة ل <strong>زيفانير</strong>.<strong> </strong></p><p>لقد ظهرت فاعلية سفدنير ضد معظم سلالات البكتيريا موجبة وسالبة الغرام: <em>فصائل ستافلوكوكس</em>، <em>ستربتوكوكس نيومونيا</em>، <em>ستربتوكوكس بيوجينز</em>، <em>ستربتوكوكس أجالاكتيا</em>، <em>وستربتوكوكس ڤيريدانز</em>، <em>هيموفيلس انفلونزا</em>، <em>هيموفيلس بارا انفلونزا</em>، <em>موراكسيلا كاتاراليس</em>، <em>نيسيريا جونوريا</em> <em>ومنينجيتيدس</em>، <em>إشيريشيا كولي</em>، <em>كلبسيلا نيومونيا</em>، <em>بروتيس ميرابيلس</em> و<em>سيتروباكتر دايڤرسس</em>.</p><p>يوصى بإستعمال <strong>زيفانير</strong> لعلاج الحالات التالية:</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي مثل إلتهاب البلعوم، إلتهاب اللوزتين، إلتهاب الجيوب الأنفية الفكية</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي السفلي مثل إلتهاب الرئة، إلتهاب القصبات التنفسية الحاد الناتج عن بكتيريا، التفاقم الحاد في إلتهاب القصبات التنفسية المزمن</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأذن الوسطى مثل إلتهاب الأذن الوسطى الحاد</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد وبنية الجلد غير المعقدة</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهابات المجاري البولية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>زيفانير</strong></p><p>إذا كنت تعاني من حساسية معروفة تجاه سفدنير، السيفالوسبورينات، البنسليات أو أي من المكونات الأخرى في <strong>زيفانير</strong>.</p><p>&nbsp;</p><p><strong>الاحتياطات</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>زيفانير</strong></p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لديك تفاعلات تحسسية مفرطة تجاه سفدنير، السيفالوسبورينات أو البنسلينات</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق حدوث إلتهاب في القولون لديك</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمنع تناول سفدنير خلال الحمل إلا إذا دعت الحاجة الواضحة لذلك (مصنف فئة &quot;ب&quot; من تصنيفات الحمل لدى دائرة الغذاء والدواء الأمريكية). لا توجد دراسات كافية ومحكمة على النساء الحوامل. لا يفرز سفدنير في حليب الأم بعد إعطاء جرعات 600 ملغم.</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور في وظائف الكلى يجب أن تخفض الجرعة اليومية من سفدنير</p><p>&nbsp;</p><p><strong>التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات</strong><strong> </strong><strong>غذائية</strong></p><p>الرجاء إخبار طبيبك او الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى حتى تلك التي يتم تناولها دون وصفة طبية.</p><p><strong>الأدوية المعدلة للحموضة و المكملات الغذائية التي تحتوي على الحديد</strong>: يجب أن تتناول <strong>زيفانير</strong> قبل أو بعد الأدوية المعدلة للحموضة أو المكملات الغذائية التي تحتوي على الحديد بساعتين على الأقل.</p><p>إذا كنت تتناول سفدنير بالتزامن مع الأدوية التي تحتوي على الحديد، قد تلاحظ أن برازك محمر؛ يرجع اللون الأحمر إلى تشكل مركبات معقدة غير قابلة للإمتصاص بين سفدنير أو منتجاته المتحللة مع الحديد في الجهاز الهضمي.</p><p><strong>بروبينيسد</strong>: بروبينيسد يمنع طرح سفدنير عن طريق الكلى وبالتالي يؤدي إلى تراكيز أعلى وعمر نصف أطول لسفدنير في الدم.</p><p>&nbsp;</p><p><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong></p><p>يمنع تناول سفدنير خلال الحمل إلا إذا دعت الحاجة الواضحة لذلك (مصنف فئة &quot;ب&quot; من تصنيفات الحمل لدى دائرة الغذاء والدواء الأمريكية). لا توجد دراسات كافية ومحكمة على النساء الحوامل. لا يفرز سفدنير في حليب الأم بعد إعطاء جرعات 600 ملغم.</p><p>إستشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p>&nbsp;</p><p><strong>معلومات هامة حول بعض مكونات</strong><strong> معلق زيفانير</strong></p><p><strong>يحتوي معلق زيفانير على 2.9 غرام سكروز تقريبا في كل 5 مل؛</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أخذ ذلك بعين الإعتبار لدى المرضى الذين يعانون من مرض السكري.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك طبيبك بعدم تحمل بعض أنواع السكر، إستشر طبيبك قبل أخذ هذا الدواء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الممكن أن يكون لسكروز تأثير ضار على الأسنان.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول <strong>زيفانير</strong> تماما كما وصفه طبيبك. يجب أن تقوم بإستشارة طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p><strong><em>الأطفال:</em></strong></p><p>الجرعة الموصى بها هي 7 ملغم/كغم من المعلق كل 12 ساعة أو 14 ملغم/كغم مرة واحدة في اليوم على أن لا تتعدى 600 ملغم في اليوم. يجب أن يعطى معلق <strong>زيفانير</strong> مرتين في اليوم في حالات إلتهاب الجلد عند الأطفال.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>وزن المريض (كغم)</strong></p></td><td style="vertical-align:top"><p><strong>الجرعة من (معلق 125ملغم/5 مل )*</strong></p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2.5 مل (0.5 ملعقة صغيرة) كل 12 ساعة أو 5 مل (ملعقة صغيرة) كل 24 ساعة</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>5 مل (ملعقة صغيرة) كل 12 ساعة أو 10 مل (ملعقتين صغيرتين) كل 24 ساعة</p></td></tr><tr><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>7.5 مل (1.5 ملعقة صغيرة) كل 12 ساعة أو 15 مل (3 ملاعق صغيرة) كل 24 ساعة</p></td></tr></tbody></table><p>* بعد تحضير المعلق</p><p>ينبغي إعطاء الأطفال الذين تزيد أوزانهم عن 43 كغم الجرعة القصوى اليومية 600 ملغم.</p><p><u>لتجهيز المعلق:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إقلب القارورة مع رج المحتوى لتفكيك البودرة, أضف الماء المغلي والمبرد الى العلامة ثم رج القارورة جيدا واكمل بالماء الى العلامة ان لزم، أعد رج القارورة جيدا حتى يتم الحصول على معلق متجانس.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تحضير المعلق لأول مرة يترك لمدة خمس دقائق للتأكد من تجانسه تماما.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رج القارورة جيدا قبل الإستعمال.</p><p><u>القصور الكلوي</u></p><p>يطرح سفدنير من الجسم عن طريق الكلى.</p><p><em>الكبار </em></p><p>عندما تكون تصفية الكرياتينين أقل من 30 مل/دقيقة، تكون الجرعة 300 ملغم <strong>زيفانير</strong> مرة واحدة يوميا.</p><p><em>الأطفال</em></p><p>يجب إعطاء الأطفال الذين تكون تصفية الكرياتينين لديهم أقل من 30 مل/دقيقة/1.73 م<sup>2</sup>: 7 ملغم/كغم <strong>زيفانير</strong> (حتى 300 ملغم) مرة واحدة يوميا.</p><p>إذا كنت تخضع &nbsp;للديلزة الدموية تكون الجرعة 300 ملغم أو 7 ملغم/كغم يوما بعد يوم.</p><p>&nbsp;</p><p><strong>الجرعة</strong><strong> </strong><strong>الزائدة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>زيفانير</strong></p><p>يتم إزالة سفدنير من الجسم عن طريق الديلزة الدموية. لا توجد معلومات كافية بخصوص فرط الجرعة في حالة سفدنير ولكن فرط الجرعة بالمضادات الحيوية البيتا-لاكتامية الأخرى قد أدت إلى حدوث غثيان، قيء، ضيق شرسوفي (فوق المعدة)، إسهال وتشنجات.</p><p>&nbsp;</p><p><strong>نسيان</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>زيفانير</strong></p><p>لا تقم بمضاعة الجرعة للتعويض عن الجرعة الفائتة.</p><p>إذا كان لديك أي أسئلة أخرى تتعلق بإستخدام هذا الدواء، يجب إستشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن الادوية الأخرى قد يسبب زيفانير أعراض جانبية على الرغم من عدم حدوثها مع جميع المرضى.</p><p>التأثيرات الجانبية بسيطة ومؤقتة بطبيعتها<strong>. </strong>اكثرها شيوعا هي إسهال، ألم في البطن، غثيان، قيء، طفح جلدي، وارتفاع مؤقت في إنزيمات الكبد.</p><p>إذا أصبحت أي من الأعراض الجانبية خطيرة أو إذا لاحظت أي أعراض جانبية لم يتم ذكرها في هذه النشرة، الرجاء إخبار طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول أيدي الاطفال ونظرهم.</p><p>لا تستخدم معلق <strong>زيفانير</strong> بعد تاريخ الانتهاء المذكور على العبوة الخارجية. يدل تاريخ الانتهاء على آخر يوم في الشهر المذكور.</p><p>يحفظ على درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p>لا تستعمل أي كمية متبقية بعد 10 أيام من تجهيز المعلق.</p><p>يجب عدم التخلص من الادوية في المياه العادمة او النفايات المنزلية. اسأل الصيدلي حول الطريقة السليمة للتخلص من الادوية التي لم تعد بحاجة اليها. سيساعد هذا في حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تحتوي كل ٥ مل على 125 ملغم سفدنير.</p><p><strong>المواد غير الفعالة</strong>: سيترات الصوديوم ثلاثي القاعدة<strong>، </strong>سيليكا غروية لامائية<strong>، </strong>ستيارات الماغنيسيوم<strong>، </strong>بنزوات الصوديوم<strong>، </strong>حمض السيتريك، سكروز<strong>، </strong>صمغ الزانثان<strong>، </strong>صمغ الجوار<strong>، </strong>نكهة الفراولة<strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوافر معلق <strong>زيفانير</strong> في زجاجات لتحضير 40 مل او 80 مل من المعلق.تحتوي على مسحوق لونه أبيض إلى مائل إلى البياض.</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة دار الدواء للتنمية والإستثمار المساهمة المحدودة (ناعور &ndash; الأردن)</p><p>هاتف: 132 27 57 (6 962 +)</p><p>فاكس: 776 27 57 (6 962 +)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            9/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xevaneer® 125 mg/5ml suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xevaneer® 125 mg/5ml suspension: After reconstitution, each 5 ml contains 125 mg Cefdinir.
For the full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off white powder for the preparation of a suspension.
Reconstituted suspension is homogeneous white to yellowish-white suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xevaneer&reg; (cefdinir) Oral Suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated micro-organisms in the conditions listed below.<br />Adults and Adolescents<br />Community-Acquired Pneumonia caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Haemophilus parainfluenzae (including &beta; -lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta; -lactamase producing strains).<br />Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenza (including &beta; -lactamase producing strains), Haemophilus parainfluenzae (including &beta; -lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), Moraxella catarrhalis (including &beta; -lactamase producing strains).<br />Acute Maxillary Sinusitis caused by Haemophilus influenzae (including &beta; -lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta; -lactamase producing strains).<br />Pharyngitis/Tonsillitis caused by Streptococcus pyogenes.<br />NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx.<br />Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated<br />to be effective for the prevention of rheumatic fever.<br />Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including &beta; -lactamase producing strains) and Streptococcus pyogenes.<br />Pediatric Patients<br />Acute Bacterial Otitis Media caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;-lactamase producing strains).<br />Pharyngitis/Tonsillitis caused by Streptococcus pyogenes<br />NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.<br />Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including &beta;-lactamase producing strains) and Streptococcus pyogenes</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder for Oral Suspension<br />The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in skin infections; therefore, Xevaneer&reg; Oral Suspension should be administered twice daily in this infection.<br />Xevaneer&reg; Oral Suspension may be administered without regard to meals.<br />Pediatric Patients (Age 6 Months Through 12 Years)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Type of Infection</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial otitis media</p></td><td style="vertical-align:top"><p>7 mg /kg q12h</p><p>Or</p><p>14 mg /kg q 24h</p></td><td style="vertical-align:top"><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute maxillary sinusitis</p></td><td style="vertical-align:top"><p>7 mg / kg q 12h</p><p>Or</p><p>14mg/kg q24 h</p></td><td style="vertical-align:top"><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis / Tonsillitis</p></td><td style="vertical-align:top"><p>7 mg/ kg q 12 h</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Or</p><p>14 mg/kg q 24 h</p></td><td style="vertical-align:top"><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated skin and skin structure infections</p></td><td style="vertical-align:top"><p>7 mg/kg q 12 h</p></td><td style="vertical-align:top"><p>10 days</p></td></tr></tbody></table><p>Xevaneer&reg; for oral suspension pediatric dosage chart</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>weight</p></td><td style="vertical-align:top"><p>125 mg/5 ml</p></td></tr><tr><td style="vertical-align:top"><p>9 kg/20 lbs</p></td><td style="vertical-align:top"><p>2.5 mL (&frac12; tsp) q12h or 5 mL (1 tsp) q24h</p></td></tr><tr><td style="vertical-align:top"><p>18 kg/40 lbs</p></td><td style="vertical-align:top"><p>5 mL (1 tsp) q12h or 10 mL (2 tsp) q24h</p></td></tr><tr><td style="vertical-align:top"><p>27 kg/60 lbs</p></td><td style="vertical-align:top"><p>7.5 mL (1&frac12; tsp) q12h or 15 mL (3 tsp) q24h</p></td></tr><tr><td style="vertical-align:top"><p>36 kg/80 lbs</p></td><td style="vertical-align:top"><p>10 mL (2 tsp) q12h or 20 mL (4 tsp) q24h</p></td></tr><tr><td style="vertical-align:top"><p>&sup3;43 kg<sup>a</sup>/95 lbs</p></td><td style="vertical-align:top"><p>12 mL (2&frac12; tsp) q12h or 24 mL (5 tsp) q24h</p></td></tr></tbody></table><p>a Pediatric patient who weigh &sup3;43 kg should receive the maximum daily dose of 600 mg.<br />Patients With Renal Insufficiency<br />Creatinine clearance is difficult to measure in outpatients. However, the following formula may be used to estimate creatinine clearance (CLcr) in adult patients. For estimates to be valid, serum creatinine levels should reflect steady-state levels of renal function.<br />Males: 𝐶𝐿𝑐𝑟=(𝑤𝑒𝑖𝑔ℎ𝑡) (140&minus;𝑎𝑔𝑒)/(72)(𝑠𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒)<br />Females: CLcr = 0.85 * above value<br />Where creatinine clearance is in mL/min, age is in years, weight is in kilograms, and serum creatinine is in mg/dL3<br />For pediatric patients with a creatinine clearance of &lt; 30 ml/min/1.73 m2, the dose of Cefdinir should be 7 mg/kg (up to 300 mg) given once daily.<br />Patients on hemodialysis<br />Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg /kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7mg /kg) should be given. Subsequent doses (300 mg or 7 mg /kg) are then administered every other day.<br />DIRECTIONS FOR MIXING CEFDINIR FOR ORAL SUSPENSION</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Final Concentration</strong></p></td><td style="vertical-align:top"><p><strong>Final Volume (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Amount of Water</strong></p></td><td style="vertical-align:top"><p><strong>Directions</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>125 mg/5 mL</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>60</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>38 ml</p></td><td rowspan="2" style="vertical-align:top"><p>Tap bottle to loosen powder,</p><p>then add water in 2 portions.</p><p>Shake well after each aliquot.</p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>63 ml</p></td></tr></tbody></table><p>Pediatric Use<br />Safety and efficacy in neonates and infants less than 6 months of age have not been established. Use of cefdinir for the treatment of acute maxillary sinusitis in pediatric patients (age 6 months through 12 years) is supported by evidence from adequate and well-controlled studies in adults<br />and adolescents, the similar pathophysiology of acute sinusitis in adult and pediatric patients, and comparative pharmacokinetic data in the pediatric population.<br />Geriatric Use<br />Efficacy is comparable in geriatric patients and younger adults. While cefdinir has been well-tolerated in all age groups, in clinical trials geriatric patients experienced a lower rate of adverse events, including diarrhea, than younger adults. Dose adjustment in elderly patients is not necessary unless renal function is markedly compromised.<br />For reconstitution:<br /> Invert the bottle and shake content to loosen powder, add pre-boiled cooled water to the mark, and shake well, then add more water if necessary up to the mark and shake well until a homogeneous suspension is obtained.<br /> When first reconstituted, allow to stand for five minutes to ensure full dispersion.<br /> Shake well before use.<br />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xevaneer® (cefdinir) is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before therapy with Xevaneer&reg; (cefdinir) is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefdinir, other cephalosporins, penicillins, or other drugs. If cefdinir is to be given to penicillin-sensitive patients, caution should be exercised because cross-hypersensitivity among &beta;-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. if an allergic reaction to cefdinir occurs, the drug should be discontinued. serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated.<br />Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefdinir, and may range in severity from mild- to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.<br />Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of &ldquo;antibiotic-associated colitis&rdquo;.<br />After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against Clostridium difficile.<br />PRECAUTIONS<br />General<br />As with other broad-spectrum antibiotics, prolonged treatment may result in the possible emergence and overgrowth of resistant organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate alternative therapy should be administered.<br />Cefdinir, as with other broad-spectrum antimicrobials (antibiotics), should be prescribed with caution in individuals with a history of colitis.<br />In patients with transient or persistent renal insufficiency (creatinine clearance &lt;30 mL/min), the total daily dose of cefdinir should be reduced because high and prolonged plasma concentrations of cefdinir can result following recommended doses<br />Information for Patients<br />Antacids containing magnesium or aluminum interfere with the absorption of cefdinir. If this type of antacid is required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid.<br />Iron supplements, including multivitamins that contain iron, interfere with the absorption of cefdinir. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement.<br />Iron-fortified infant formula does not significantly interfere with the absorption of cefdinir. Therefore, Xevaneer&reg; Oral Suspension can be administered with iron fortified infant formula.<br />Xevaneer&reg; suspension contains approximately 2.9 grams sucrose per 5 ml;<br /> This should be taken into account in patients with diabetes mellitus.<br /> If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.<br /> Sucrose may be harmful to the teeth.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antacids: (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox&reg; TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. Time to reach Cmax is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid.<br />Probenecid: As with other &beta;-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.<br />Iron Supplements and Foods Fortified with Iron: Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied. Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6<br />oz) has no significant effect on cefdinir pharmacokinetics. Therefore, cefdinir for Oral Suspension can be administered with iron-fortified infant formula.<br />There have been rare reports of reddish stools in patients who have received cefdinir in Japan. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.<br />Drug/Laboratory Test Interactions<br />A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest&reg;, Benedict&rsquo;s solution, or Fehling&#39;s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix&reg; or Tes-Tape&reg;) be used. Cephalosporins are known to occasionally induce a positive direct Coombs&rsquo; test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy - Teratogenic Effects<br />Pregnancy Category B: Cefdinir was not teratogenic in rats at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day) or in rabbits at oral doses up to 10 mg/kg/day (0.7 times the human dose based on mg/kg/day, 0.23 times based on mg/m2/day). Maternal toxicity (decreased body weight gain) was observed in rabbits at the maximum tolerated dose of 10 mg/kg/day without adverse effects on offspring. Decreased body weight occurred in rat fetuses at  100 mg/kg/day, and in rat offspring at  32 mg/kg/day. No effects were observed on maternal reproductive parameters or offspring survival, development, behavior, or reproductive function.<br />There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.<br />Labor and Delivery<br />Cefdinir has not been studied for use during labor and delivery.<br />Nursing Mothers<br />Following administration of single 600-mg doses, cefdinir was not detected in human breast milk.<br />In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse effects on the ability to drive or operate machinery have not been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trials &ndash; cefdinir for Oral Suspension (Pediatric Patients):<br />In clinical trials, 2289 pediatric patients (1783 US and 506 non-US) were treated with the recommended dose of cefdinir suspension (14 mg/kg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir.<br />Forty of 2289 (2%) patients discontinued medication due to adverse events considered by the investigators to be possibly, probably, or definitely associated with cefdinir therapy.<br />Discontinuations were primarily for gastrointestinal disturbances, usually diarrhea.<br />Five of 2289 (0.2%) patients were discontinued due to rash thought related to cefdinir administration.<br />In the US, the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir suspension in multiple-dose clinical trials<br />(N = 1783 cefdinir-treated patients):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>EVENTS ASSOCIATED WITH CEFDINIR SUSPENSION</p><p>US TRIALS IN PEDIATRIC PATIENTS</p><p>(N = 1783)<sup>a</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Incidence &ge;1%</p></td><td style="vertical-align:top"><p>Diarrhea</p><p>Rash</p><p>Vomiting</p></td><td style="vertical-align:top"><p>8%</p><p>3%</p><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Incidence &lt;1% but &gt;0.1%</p></td><td style="vertical-align:top"><p>Cutaneous moniliasis</p><p>Abdominal pain</p><p>Leukopenia<sup>b</sup></p><p>Vaginal moniliasis</p><p>Vaginitis</p><p>Abnormal stools</p><p>Dyspepsia</p><p>Hyperkinesia</p><p>Increased AST<sup>b</sup></p><p>Maculopapular rash</p><p>Nausea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.9%</p><p>0.8%</p><p>0.3%</p><p>0.3% of girls</p><p>0.3% of girls</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p></td></tr></tbody></table><p>a 977 males, 806 females<br />b Laboratory changes were occasionally reported as adverse events<br />.<br />NOTE: In both cefdinir- and control-treated patients, rates of diarrhea and rash were higher in the youngest pediatric patients. The incidence of diarrhea in cefdinir-treated patients 2 years of age was 17% (95/557) compared with 4% (51/1226) in those &gt;2 years old. The incidence of rash (primarily diaper rash in the younger patients) was 8% (43/557) in patients 2 years of age compared with 1% (8/1226) in those &gt;2 years old.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The following laboratory value changes of possible clinical significance, irrespective of</p><p>relationship to therapy with cefdinir, were seen during clinical trials conducted in the US:</p><p>LABORATORY VALUE CHANGES OF POSSIBLE CLINICAL SIGNIFICANCE</p><p>OBSERVED WITH CEFDINIR SUSPENSION</p><p>US TRIALS IN PEDIATRIC PATIENTS</p><p>(N = 1783)<sup>a</sup></p><p><strong>Incidence </strong><strong>&sup3;</strong><strong>1% </strong></p><p>&shy; Lymphocytes, &macr; Lymphocytes 2%, 0.8%</p><p>&shy; Alkaline phosphatase 1%</p><p>&macr; Bicarbonate<sup>a</sup> 1%</p><p>&shy; Eosinophils 1%</p><p>&shy; Lactate dehydrogenase 1%</p><p>&shy; Platelets 1%</p><p>&shy; PMNs, &macr; PMNs 1%, 1%</p><p>&shy; Urine protein 1%</p><p><strong>Incidence &lt;1% but &gt;0.1%</strong></p><p>&shy; Phosphorus, &macr; Phosphorus 0.9%, 0.4%</p><p>&shy; Urine pH 0.8%</p><p>&macr; White blood cells, &shy; White blood cells 0.7%, 0.3%</p><p>&macr; Calcium<sup>a</sup> 0.5%</p><p>&macr; Hemoglobin 0.5%</p><p>&shy; Urine leukocytes 0.5%</p><p>&shy; Monocytes 0.4%</p><p>&shy; AST 0.3%</p><p>&shy; Potassium<sup>a</sup> 0.3%</p><p>&shy; Urine specific gravity, &macr; Urine specific gravity 0.3%, 0.1%</p><p>&macr; Hematocrit<sup>a</sup> 0.2%</p><p>a N = 1387 for these parameters.<strong> </strong></p></td></tr></tbody></table><p>Post marketing Experience<br />The following adverse experiences and altered laboratory tests, regardless of their relationship to cefdinir, have been reported during extensive postmarketing experience, beginning with approval in Japan in 1991: Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, erythema nodosum, conjunctivitis, stomatitis, acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, increased amylase, shock, anaphylaxis, facial and laryngeal edema, feeling of suffocation, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, melena, pseudomembranous colitis, pancytopenia, granulocytopenia, leukopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, idiopathic interstitial pneumonia, fever, acute renal failure, nephropathy, bleeding tendency, coagulation disorder, disseminated intravascular coagulation, upper GI bleed, peptic ulcer, ileus, loss of consciousness, allergic vasculitis, possible cefdinir-<br />diclofenac interaction, cardiac failure, chest pain, myocardial infarction, hypertension, involuntary movements, and rhabdomyolysis.<br />Cephalosporin Class Adverse Events<br />The following adverse events and altered laboratory tests have been reported for cephalosporin-class antibiotics in general:<br />Allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for urinary glucose, neutropenia, pancytopenia, and agranulocytosis. Pseudomembranous colitis symptoms may begin during or after antibiotic treatment. Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.<br />To report any side effects:<br /> National Pharmacovigilance and Drug Safety Centre (NPC)<br /> Fax: + 966 112057662<br /> Call NPC at + 966 112038222, Exts: 2317-2356-2353-2354-2334-2340<br /> Toll free phone: 8002490000<br /> E-mail: npc.drug@sfda.gov.sa<br /> Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600-mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other &beta;-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis removes cefdinir from the body. This may be useful in the event of a serious toxic reaction from overdosage, particularly if renal function is compromised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antibacterials for systemic use, other beta-lactam antibacterials, third-generation cephalosporins, ATC code: J01DD15.<br />As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, &beta;-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.<br />Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections<br />Aerobic Gram-Positive Microorganisms:<br />Staphylococcus aureus (including &beta;-lactamase producing strains)<br />NOTE: Cefdinir is inactive against methicillin-resistant staphylococci.<br />Streptococcus pneumoniae (penicillin-susceptible strains only)<br />Streptococcus pyogenes<br />Aerobic Gram-Negative Microorganisms:<br />Haemophilus influenzae (including &beta;-lactamase producing strains)<br />Haemophilus parainfluenzae (including &beta;-lactamase producing strains)<br />Moraxella catarrhalis (including &beta;-lactamase producing strains)<br />The following in vitro data are available, but their clinical significance is unknown.<br />Cefdinir exhibits in vitro minimum inhibitory concentrations (MICs) of 1 &mu;g/mL or less against (90%) strains of the following microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.<br />Aerobic Gram-Positive Microorganisms:<br />Staphylococcus epidermidis (methicillin-susceptible strains only)<br />Streptococcus agalactiae<br />Viridans group streptococci<br />NOTE: Cefdinir is inactive against Enterococcus and methicillin-resistant<br />Staphylococcus species.<br />Aerobic Gram-Negative Microorganisms:<br />Citrobacter diversus<br />Escherichia coli<br />Klebsiella pneumoniae<br />Proteus mirabilis<br />NOTE: Cefdinir is inactive against Pseudomonas and Enterobacter species.<br />Susceptibility Tests:<br />Dilution Techniques: Quantitative methods are used to determine antimicrobial<br />minimum inhibitory concentrations (MICs). These MICs provide estimates of the<br />susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefdinir powder. The MIC values should be interpreted according to the following criteria:<br />For organisms other than Haemophilus spp. and Streptococcus spp:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>MIC (&mu;g/mL)</p></td><td style="vertical-align:top"><p>Interpretation</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>Susceptible (S)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>Intermediate (I)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 4</p></td><td style="vertical-align:top"><p>Resistant (R)</p></td></tr></tbody></table><p>For Haemophilus spp:a</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>MIC (&mu;g/mL)</p></td><td style="vertical-align:top"><p>Interpretation <sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>Susceptible (S)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>a These interpretive standards are applicable only to broth microdilution susceptibility tests with <em>Haemophilus </em>spp. using <em>Haemophilus </em>Test Medium (HTM).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>b The current absence of data on resistant strains precludes defining any results other than &ldquo;Susceptible&rdquo;. Strains yielding MIC results suggestive of a &ldquo;nonsusceptible&rdquo; category should be submitted to a reference laboratory for further testing</p></td></tr></tbody></table><p>For Streptococcus spp:<br />Streptococcus pneumoniae that are susceptible to penicillin (MIC  0.06 &mu;g/mL), or streptococci other than S. pneumoniae that are susceptible to penicillin (MIC  0.12 &mu;g/mL), can be considered susceptible to cefdinir. Testing of cefdinir against penicillin-intermediate or penicillin-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.<br />A report of &ldquo;Susceptible&rdquo; indicates that the pathogen is likely to be inhibited if the<br />antimicrobial compound in the blood reaches the concentration usually achievable. A report of &ldquo;Intermediate&rdquo; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of &ldquo;Resistant&rdquo; indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.<br />Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. Standard cefdinir powder should provide the following MIC values:&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Micro-organism</p></td><td style="vertical-align:top"><p>MIC Range (&mu;g/mL)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Escherichia coli </em>ATCC 25922</p></td><td style="vertical-align:top"><p>0.12-0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em>ATCC 49766<sup>c</sup></p></td><td style="vertical-align:top"><p>0.12-0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>ATCC 29213</p></td><td style="vertical-align:top"><p>0.12-0.5</p></td></tr></tbody></table><p>c This quality control range is applicable only to H. influenzae<br />ATCC 49766 tested by a broth microdilution procedure using HTM.<br />Diffusion Techniques: Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure2 requires the use of standardized inoculum concentrations.<br />This procedure uses paper disks impregnated with 5-&mu;g cefdinir to test the susceptibility of microorganisms to cefdinir.<br />Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5-&mu;g cefdinir disk should be interpreted according to the following criteria:<br />For organisms other than Haemophilus spp. and Streptococcus spp:d&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Zone Diameter (mm)</p></td><td style="vertical-align:top"><p>Interpretation</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 20</p></td><td style="vertical-align:top"><p>Susceptible (S)</p></td></tr><tr><td style="vertical-align:top"><p>17-19</p></td><td style="vertical-align:top"><p>Intermediate (I)</p></td></tr><tr><td style="vertical-align:top"><p>&le; 16</p></td><td style="vertical-align:top"><p>Resistant (R)</p></td></tr></tbody></table><p>d Because certain strains of Citrobacter, Providencia, and Enterobacter spp. have been reported to give false susceptible results with the cefdinir disk, strains of these genera should not be tested and reported with this disk.<br />For Haemophilus spp&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Zone Diameter (mm)</p></td><td style="vertical-align:top"><p>Interpretation f</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 20</p></td><td style="vertical-align:top"><p>Susceptible (S)</p><p>&nbsp;</p></td></tr></tbody></table><p>e These zone diameter standards are applicable only to tests with Haemophilus spp. using HTM.2<br />f The current absence of data on resistant strains precludes defining any results other than &ldquo;Susceptible.&rdquo; Strains yielding &ldquo;MIC deleted&rdquo; results suggestive of a &ldquo;nonsusceptible&rdquo; category should be submitted to a reference laboratory for further testing.<br />For Streptococcus spp:<br />Isolates of Streptococcus pneumoniae should be tested against a 1-&mu;g oxacillin disk.<br />Isolates with oxacillin zone sizes  20 mm are susceptible to penicillin and can be considered susceptible to cefdinir. Streptococci other than S. pneumoniae should be tested with a 10-unit penicillin disk. Isolates with penicillin zone sizes  28 mm are susceptible to penicillin and can be considered susceptible to cefdinir.<br />As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. For the diffusion technique the 5-&mu;g cefdinir disk should provide the following zone diameters in these laboratory quality control strains:&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Organism</p></td><td style="vertical-align:top"><p>Zone Diameter (mm)</p></td></tr><tr><td style="vertical-align:top"><p><em>Escherichia coli </em>ATCC 25922</p></td><td style="vertical-align:top"><p>24-28</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em>ATCC 49766g</p></td><td style="vertical-align:top"><p>24-31</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>ATCC 25923</p></td><td style="vertical-align:top"><p>25-32</p></td></tr></tbody></table><p>g This quality control range is applicable only to testing of H. influenzae<br />ATCC 49766 using HTM.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:<br />Oral Bioavailability: Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from 300 mg (7 mg/kg) to 600 mg (14 mg/kg). Following administration of suspension to healthy adults, cefdinir bioavailability is 120% relative to capsules. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%.<br />Effect of Food: Although the rate (Cmax) and extent (AUC) of cefdinir absorption from the capsules are reduced by 16% and 10%, respectively, when given with a high-fat meal, the magnitude of these reductions is not likely to be clinically significant. Therefore, cefdinir may be taken without regard to food.<br />Cefdinir Capsules: Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 300- and 600-mg oral doses of cefdinir to adult subjects are presented in the following table:<br />Mean (&plusmn; SD) Plasma Cefdinir Pharmacokinetic Parameter<br />Values Following Administration of Capsules to Adult Subjects&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Cmax</p><p>(&mu;g/mL)</p></td><td style="vertical-align:top"><p>tmax</p><p>(hr)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>AUC</p><p>(&mu;g - hr/mL)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>300 mg</p></td><td style="vertical-align:top"><p>1.60</p><p>(0.55)</p></td><td style="vertical-align:top"><p>2.9</p><p>(0.89)</p></td><td style="vertical-align:top"><p>7.05</p><p>(2.17)</p></td></tr><tr><td style="vertical-align:top"><p>600 mg</p></td><td style="vertical-align:top"><p>2.87</p><p>(1.01)</p></td><td style="vertical-align:top"><p>3.0</p><p>(0.66)</p></td><td style="vertical-align:top"><p>11.1</p><p>&nbsp;(3.87)</p></td></tr></tbody></table><p>Cefdinir Suspension: Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 7- and 14-mg/kg oral doses of cefdinir to pediatric subjects (age 6 months-12 years) are presented in the following table:<br />Mean (&plusmn;SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following<br />Administration of Suspension to Pediatric Subjects&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Cmax</p><p>(&mu;g/mL)</p></td><td style="vertical-align:top"><p>tmax</p><p>(hr)</p></td><td style="vertical-align:top"><p>AUC</p><p>(&mu;g - hr/mL)</p></td></tr><tr><td style="vertical-align:top"><p>7 mg/kg</p></td><td style="vertical-align:top"><p>2.30</p><p>(0.65)</p></td><td style="vertical-align:top"><p>2.2</p><p>(0.6)</p></td><td style="vertical-align:top"><p>8.31</p><p>(2.50)</p></td></tr><tr><td style="vertical-align:top"><p>14 mg/kg</p></td><td style="vertical-align:top"><p>3.86</p><p>(0.62)</p></td><td style="vertical-align:top"><p>1.8</p><p>(0.4)</p></td><td style="vertical-align:top"><p>13.4</p><p>(2.64)</p></td></tr></tbody></table><p>Multiple Dosing: Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.<br />Distribution The mean volume of distribution (Vdarea) of cefdinir in adult subjects is 0.35 L/kg (&plusmn; 0.29); in pediatric subjects (age 6 months-12 years), cefdinir Vd area is<br />0.67 L/kg (&plusmn; 0.38). Cefdinir is 60% to 70% bound to plasma proteins in both adult and pediatric subjects; binding is independent of concentration.<br />Skin Blister: In adult subjects, median (range) maximal blister fluid cefdinir concentrations of 0.65 (0.33-1.1) and 1.1 (0.49-1.9) &mu;g/mL were observed 4 to 5 hours following administration of 300- and 600-mg doses, respectively. Mean (&plusmn; SD) blister Cmax and AUC (0-) values were 48% (&plusmn;13) and 91% (&plusmn;18) of corresponding plasma values.<br />Tonsil Tissue: In adult patients undergoing elective tonsillectomy, respective median tonsil tissue cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were 0.25 (0.22-0.46) and 0.36 (0.22-0.80) &mu;g/g. Mean tonsil tissue concentrations were 24% (&plusmn;8) of corresponding plasma concentrations.<br />Sinus Tissue: In adult patients undergoing elective maxillary and ethmoid sinus surgery, respective median sinus tissue cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were &lt;0.12 (&lt;0.12-0.46) and 0.21 (&lt;0.12-2.0) &mu;g/g. Mean sinus tissue concentrations were 16% (&plusmn;20) of corresponding plasma concentrations.<br />Lung Tissue: In adult patients undergoing diagnostic bronchoscopy, respective median bronchial mucosa cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were 0.78 (&lt;0.06-1.33) and 1.14 (&lt;0.06-1.92) &mu;g/mL, and were 31% (&plusmn;18) of corresponding plasma concentrations. Respective median epithelial lining fluid concentrations were 0.29 (&lt;0.3-4.73) and 0.49 (&lt;0.3-0.59) &mu;g/mL, and were 35% (&plusmn;83) of corresponding plasma concentrations.<br />Middle Ear Fluid: In 14 pediatric patients with acute bacterial otitis media, respective median middle ear fluid cefdinir concentrations 3 hours after administration of single 7- and 14-mg/kg doses were 0.21 (&lt;0.09-0.94) and 0.72 (0.14-1.42) &mu;g/mL. Mean middle ear fluid concentrations were 15% (&plusmn;15) of corresponding plasma concentrations.<br />CSF: Data on cefdinir penetration into human cerebrospinal fluid are not available.<br />Metabolism and Excretion: Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t&frac12;) of 1.7 (&plusmn;0.6) hours. In healthy subjects with normal renal function, renal clearance is 2.0 (&plusmn;1.0) mL/min/kg, and apparent oral clearance is 11.6 (&plusmn;6.0) and 15.5 (&plusmn;5.4) mL/min/kg following doses of 300 and 600 mg, respectively. Mean percent of dose recovered unchanged in the urine following 300- and 600-mg doses is 18.4% (&plusmn;6.4) and 11.6% (&plusmn;4.6), respectively. Cefdinir clearance is reduced in patients with renal dysfunction<br />Because renal excretion is the predominant pathway of elimination, dosage should be adjusted in patients with markedly compromised renal function or who are undergoing hemodialysis.<br />Special Populations: Patients with Renal Insufficiency: Cefdinir pharmacokinetics were investigated in 21 adult subjects with varying degrees of renal function. Decreases in cefdinir elimination rate, apparent oral clearance (CL/F), and renal clearance were approximately proportional to the reduction in creatinine clearance (CLcr). As a result, plasma cefdinir concentrations were higher and persisted longer in subjects with renal impairment than in those without renal impairment. In subjects with CLcr between 30 and 60 mL/min, Cmax and t&frac12; increased by approximately 2-fold and AUC by approximately 3-fold. In subjects with CLcr &lt;30 mL/min, Cmax increased by approximately 2-fold, t&frac12; by pproximately 5-fold, and AUC<br />by approximately 6-fold. Dosage adjustment is recommended in patients with markedly compromised renal function (creatinine clearance &lt;30 mL/min)<br />Hemodialysis: Cefdinir pharmacokinetics were studied in 8 adult subjects undergoing hemodialysis. Dialysis (4 hours duration) removed 63% of cefdinir from the body and reduced apparent elimination t&frac12; from 16 (&plusmn;3.5) to 3.2 (&plusmn;1.2) hours. Dosage adjustment is recommended in this patient population<br />Hepatic Disease: Because cefdinir is predominantly renally eliminated and not appreciably metabolized, studies in patients with hepatic impairment were not conducted.<br />It is not expected that dosage adjustment will be required in this population.<br />Geriatric Patients: The effect of age on cefdinir pharmacokinetics after a single 300-mg dose was evaluated in 32 subjects 19 to 91 years of age. Systemic exposure to cefdinir was substantially increased in older subjects (N = 16), Cmax by 44% and AUC by 86%. This increase was due to a reduction in cefdinir clearance. The apparent volume of distribution was also reduced, thus no appreciable alterations in apparent elimination half-life were observed (elderly: 2.2 &plusmn; 0.6 hours vs young: 1.8 &plusmn; 0.4 hours). Since cefdinir clearance has been shown to be primarily related to changes in renal function rather than age, elderly patients do not require dosage adjustment unless they have markedly compromised renal function (creatinine clearance &lt;30 mL/min).<br />Gender and Race: The results of a meta-analysis of clinical pharmacokinetics (N = 217) indicated no significant impact of either gender or race on cefdinir pharmacokinetics.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The carcinogenic potential of cefdinir has not been evaluated. No mutagenic effects were seen in the bacterial reverse mutation assay (Ames) or point mutation assay at the hypoxanthine-guanine phosphoribosyltransferase locus (HGPRT) in V79 Chinese hamster lung cells. No clastogenic effects were observed in vitro in the structural chromosome aberration assay in V79 Chinese hamster lung cells or in vivo in the micronucleus assay in mouse bone marrow. In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tribasic sodium citrate, colloidal anhydrous silica, magnesium stearate, sodium benzoate, citric acid, sucrose, xanthan gum, guar gum, strawberry flavor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.<br />For suspension: Discard unused content 10 days after reconstitution</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glass amber bottle with a plastic CRC cap with induction enclosed in a carton box along with an insert.<br />Xevaneer&reg; suspension is available in bottles containing powder sufficient to prepare 40 ml or 80 ml suspension.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co. Ltd.
P.O. Box 9364
Na'ur – Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/09/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>